HLB’s investigational anticancer drug, rivoceranib, proved the safety as a second-line treatment in gastric cancer in a phase 1 trial, according to an abstract partially released before the annual meeting of the European Society for Medical Oncology this Friday.
Please refer to the following website for further details: